Finorify

HALO

Halozyme Therapeutics

$77.53+2.26%

Price

HALO daily closing price
Market cap
$9.2 billion
P/E (TTM)
12.75
EV/EBITDA
9.57
Volume
1.5M
Sector
Healthcare

Halozyme Therapeutics (HALO) last closed at $77.53, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for HALO, covered for search and blurred for visitors.

Performance

  • 1D+0.37%
  • 5D+6.86%
  • 1M+8.43%
  • 3M+54.42%
  • 6M+82.50%
  • 1Y+87.80%
  • 5Y+238.29%

Financials

HALO revenueQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, Halozyme Therapeutics reported revenue of $1.54 billion.

The prior window totaled $982.2 million, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $699.3 million.

Free cash flow in the latest window was $686.8 million.

These amounts are taken from Halozyme Therapeutics's SEC filings and are a snapshot as of August 13, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE 160.2% (100 of 100). Cash generation: FCF margin 44.7% (89 of 100). Net margin: 47.8% (100 of 100). Liquidity: Current 2.71× (100 of 100).

Cash Flow

HALO free cash flowQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Margins

HALO operating margin

Valuation

P/E (TTM)
12.75
P/S (TTM)
5.75
EV/EBITDA
9.57

Insights

Finorify has not written notes for HALO in this snapshot.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open HALO in Finorify